FOR INSTITUTIONS

What Happens After Discharge?

Treatment saves lives.

The question is what happens next.

Recovery does not end when treatment ends. Yet for many organizations, the period after discharge remains largely invisible, difficult to verify, and disconnected from any structured continuity infrastructure.

The result is not necessarily clinical failure.

The result is continuity exposure.

THE SHIFT

The Risk Does Not End When Treatment Ends.
It Changes Hands.

Once a client leaves treatment, recovery unfolds in the environment where life actually happens — work, family systems, housing, relationships, community, and daily stress.

This is where long-term outcomes are ultimately decided.

And yet for much of the field, continuity beyond discharge remains largely voluntary, fragmented, and difficult to verify.

Treatment addresses the episode.
Recovery is decided across time.

EXPOSURE

Invisibility Is Not Neutral.
It Is Exposure.

What cannot be seen cannot be measured.
What cannot be measured cannot be defended.
And what cannot be defended becomes institutional risk.
Financial. Operational. Reputational. Potentially legal.
Employers & EAPs
Return-to-work is not resolution.
Union Health & Welfare Funds
Fiduciary duty extends beyond negotiation.
Family Offices
Capital deployed without continuity does not establish stability.
Treatment Centers
Many of the outcomes institutions ultimately care about unfold after discharge.
×
FOR EMPLOYERS AND EMPLOYEE ASSISTANCE PROGRAMS You Funded the Benefit. Do You Know What It Produced?
Employers and EAPs occupy distinct and consequential positions in the treatment referral chain.

The EAP assesses, refers, and coordinates.

The employer governs leave, return to work, performance, and safety.

Yet once the individual enters treatment, both are often left without a clear view of what happens next.
What happens after discharge—the period when recovery is most fragile and risk is highest—is invisible to the institutions that funded and directed the treatment episode.
That gap can persist through return to work, precisely when recovery stability begins to intersect with attendance, performance, safety, and continued employment.
The consequences are not neutral.

They create workforce and governance exposure for the employer—and referral and professional-accountability exposure for the EAP.
When an employee returns to work under a return-to-work agreement and something goes wrong in month seven—relapse, safety incident, termination—the question that follows is precise:

What did your institution know about what the treatment produced?
If the answer is nothing, the employer may be unable to demonstrate how it governed the return to work—and the EAP may be unable to demonstrate how it evaluated the referral beyond placement.
What Employers Are Absorbing Without Knowing It Substance use disorders cost employers an estimated $93 billion annually in lost productivity alone.

Those costs do not necessarily end when treatment is completed. They may continue through absence, impaired performance, turnover, recurrence, workplace disruption, and unsuccessful reintegration.

In effect, employers are funding a system that transfers the risk back to them at the moment of discharge—without providing the tools to manage it.
What EAPs Are Not Measuring EAPs measure utilization.
They do not measure outcomes.

An EAP that refers into a treatment network without six-month, provider-level outcome evidence has completed a transaction—not longitudinal due diligence.
The Question That Is Coming Value-based care, behavioral health parity enforcement, and an evolving litigation landscape are converging on the same standard:

Referral is not the deliverable.
Outcome accountability is.

The institutions that begin building visibility into post-discharge outcomes now—before the regulatory environment requires it, before a bad outcome makes it a legal question—will be able to answer when asked.

The institutions that wait will not be waiting for a better time.

They will be waiting for worse outcomes.
The Mechanism The Institutional Continuity Assessment™ is the formal process through which employers and EAPs establish visibility into the post-discharge outcome infrastructure of their treatment provider relationships.

It is not a consulting engagement.

It is a structural determination.
×
FOR UNION HEALTH AND WELFARE FUNDS
You Negotiated the Benefit.
Do You Know If It Works?
The Declaration (Start Here) +
When a union negotiates an addiction treatment benefit, it represents a consequential commitment of bargaining authority and benefit resources..

That commitment carries obligations — fiduciary, representational, and political — that most union funds have not fully examined in the context of addiction treatment.
The Fiduciary Obligation +
Union health and welfare funds — particularly Taft-Hartley funds — carry explicit fiduciary obligations to their beneficiaries.

Trustees are required to act in the interest of fund participants.

That standard applies to how the fund's assets are deployed — including the treatment benefits those assets fund.

Where trustees cannot evaluate how a benefit performs beyond utilization and payment, a meaningful oversight and evidentiary gap may remain.

Regulators and plaintiffs' attorneys have consistently followed the money into areas where institutional actors were making consequential decisions without adequate accountability structures:

Pharmacy benefit management
Mental health parity compliance
Network adequacy standards

Addiction-treatment benefits are increasingly examined within broader expectations concerning parity, benefit administration, quality, and accountability.
The Representational Obligation +
Unions have a duty of fair representation.

When a member uses the addiction treatment benefit the union negotiated, receives treatment, returns to work, and subsequently relapses — the union's posture in any resulting grievance, arbitration, or termination proceeding is shaped by what it knows about the quality and continuity of the treatment that member received.

If the union knows nothing — because no one tracked outcomes — its ability to advocate effectively is compromised.

It cannot argue that the treatment failed if it has no evidence.
It cannot challenge a termination without post-discharge data.
It cannot make a credible argument for a second treatment opportunity without understanding why the first did not hold.
The Political Obligation +
A union membership that watches a brother or sister go through treatment, return to work, relapse, and lose their job — and then asks what the union did to ensure the treatment actually worked — is a membership with a legitimate grievance.

Not a formal one.

An ethical one.

The addiction treatment benefit deserves the same scrutiny the pension fund gets.
The same oversight pharmacy benefits receive.
The same accountability standard applied everywhere else.
The Mechanism +
The Institutional Continuity Assessment™ is the formal process through which union funds and trustees establish documented evidence that the treatment benefit they negotiated produces measurable, longitudinal outcomes.

It provides a structured governance record that can support documented oversight of the treatment benefit.

Because in the absence of evidence, the system does not default to trust.

It defaults to scrutiny.
×
FOR FAMILY OFFICES & PRIVATE CLIENT ADVISORS

You Protect Generational Wealth.
Trauma Transfers Too.

Family offices manage capital across generations.
Substance use disorder moves the same way.

THE ENGAGEMENT

When a principal, a beneficiary, or a key executive enters treatment, your office does what it is designed to do:

You fund the placement. You coordinate the logistics. You ensure access to the best available care.

And when the episode ends, you receive a discharge summary.

Operationally, the engagement is complete.

THE GAP

But recovery does not end at discharge.

That is where outcomes are decided.

What happens next — whether stability holds or collapses — sits outside the system you oversee.

No reporting. No verification. No continuity of accountability.

The phase that determines whether the intervention worked is structurally invisible.

THE CONSEQUENCE

That invisibility is not benign.

It is where recurrence begins.

Repeated placements.
Interventions escalate.
Trust erodes across the family system — quietly, then all at once.

Not because the resources were insufficient.

But because the system stopped tracking the outcome at the point it mattered most.

THE EXPOSURE

The financial exposure has a number.

The reputational exposure does not — until the moment it does.

And at that moment, the number is no longer the primary problem.

THE ESCALATION

A principal in active recurrence does not remain contained.

It surfaces.
In boardrooms.
In succession conversations.
In the room where control of the next generation is being determined.

At that point, this is no longer a private matter.

It is a governance issue.

THE DECISION WINDOW

Because the estate does not wait for recovery.

Capital continues to move.
Decisions continue to be made.
Authority continues to shift — whether stability is present or not.

If instability is present in that moment, it does not stay isolated.

It enters the system that allocates capital.

It influences judgment.

It alters decisions that cannot be reversed.

By the time it is visible, it is no longer a clinical problem.

It is a structural one — and it is already governing decisions.

THE STANDARD

Funding care is not the end of stewardship.

The governing question is whether stability can be observed and supported across time.

THE MECHANISM

The Institutional Continuity Assessment™ does not advise.

It determines whether the treatment relationships your office funds have the structural capacity to observe, support, and evidence continuity beyond discharge — or whether the relationship effectively ends when the treatment episode does.

Because if continuity is your mandate — what happens after discharge is not peripheral to oversight.

It is central to responsible care stewardship and capital allocation.

And right now, it is:
Unmeasured.
Unverified.
Unaccounted For.

Which means one of two things is true:

Either the outcomes are being produced — and no one is confirming them.

Or they are not — and the system continues to fund the same point of failure.

In either case, the risk is already inside the structure.

The question is not whether to evaluate it.

It is whether you will determine it — or continue to operate without seeing it.

×
FOR TREATMENT CENTERS

The Organizations That Define
What Comes Next
Are Already Building It.

The Model
Most treatment systems were designed to stabilize.

That was the standard.

The standard has shifted.

Episodic outcomes limit what your organization can prove, sustain, and scale.

What happens after clients leave is rarely visible to the organization that provided care.

Which means results are not verified —
they are assumed.
The Question
Before anything else — one question determines everything:

What happens to your clients when the episode ends?
Why Longitudinal Design Matters
Most treatment systems are organized around episodes of care:

Detox → Residential → PHP → IOP → Discharge

But recovery does not conform to episodic timelines.

The American Society of Addiction Medicine's 4th Edition did not simply refine placement criteria.

It strengthened the chronic-care model through long-term remission monitoring, recovery-management checkups, and access to recovery-support services across the continuum.

The organizations that will define the next era of behavioral health will not be those that stabilize fastest —
but those that sustain recovery longest.

Longitudinal design is not simply a clinical refinement.

It is a structural shift.

Longitudinal systems create greater capacity to observe, support, and substantiate what occurs beyond the treatment episode.
What This Enables
Centers that extend structured continuity beyond discharge gain the ability to:

Demonstrate measurable long-term outcomes
Build alumni infrastructure that functions as accountability
Strengthen referral confidence through sustained results
Establish credibility rooted in structured follow-through
Invest meaningfully in extended recovery support
Show readiness for value-based reimbursement models

Continuity is not a safeguard.
It is infrastructure.

When growth is built on sustained recovery rather than episodic completion, it becomes structurally aligned with outcome reality.
The Mechanism
The Institutional Continuity Assessment™ evaluates whether a verifiable continuity architecture exists beyond discharge and how effectively clients connect to it.

It is not a consulting engagement.

It is a structural determination.
Structural Exposure

The highest-risk period
is often the least visible.

When continuity after discharge is left unmeasured and unsupported, recurrence, repeat admissions, reputational damage, and transaction scrutiny become leadership issues.

THE CONTINUITY GAP
Every organization eventually encounters the same question.
What happens after discharge?
Not immediately.
Six months later.
Twelve months later.
When stress returns.
When family systems re-engage.
When life resumes.
The challenge is not whether treatment was provided.
The challenge is whether a verifiable continuity architecture exists beyond the treatment episode.
Because recovery outcomes are ultimately determined in the environment where people live, work, and rebuild their lives.
When continuity cannot be verified, exposure remains.
Not because treatment failed.
Because continuity was never measured.

Institutional Continuity Assessment

Most institutions cannot answer what happens after discharge.

Not because they don't care.

Because they weren't designed to measure.

The Institutional Continuity Assessment™ changes that.

It establishes an independent structural determination
of institutional continuity beyond the treatment episode.

This assessment determines what most systems are structurally unable to see.

It evaluates how an organization's operational model functions across time —

whether continuity is structurally integrated, partially established, or absent beyond the treatment episode.

Recovery does not unfold in 30, 60, or 90-day increments.

Systems that assume it does cannot account for what unfolds beyond it.

Systems built solely around the treatment episode
are structurally unable to evaluate
continuity across time.
Treatment ends at discharge.
Recovery begins there.
The ICA™ determines whether those two realities connect.

Assessment Criteria

This assessment does not measure amenities.

It does not require a reorganization of your treatment model or clinical processes.

It determines whether the organization has the infrastructure to observe, support, and evidence continuity beyond discharge.

What unfolds across time can only be measured across time.

ICA™ · ECONOMIC VISIBILITY

Continuity Economics

The treatment industry measures the value of the admission. The ICA™ examines whether that value is sustained across time.

WHAT THE EXHIBIT MAKES VISIBLE

EBITDA can describe operating performance. Alongside ordinary financial and operating reports, an organization can see what it earned, what it spent, how full it was, and how efficiently activity converted into margin.

What those reports cannot establish is whether the activity producing that performance reflects durable stability or recycled instability.

Are referral accounts sustained?
Does care continue across transitions?
Can returning activity be distinguished from new demand?
Does apparent census stability reflect durable underlying relationships?

The Continuity Economics Exhibit examines that missing layer.

Using organization-supplied records, the Exhibit examines the economic patterns beneath admissions and acquisition activity, including where the record is complete and where material limitations remain.

An admission is a single recorded event. On its own, it does not establish whether the episode represents a first admission or a return to care, whether the person continued into further care, or whether the source that produced the admission reflects a durable referral relationship.

The Exhibit examines what ordinary admission reporting may leave unstated, and where the institution's own data cannot resolve it.

Brought together, these ordinarily separated records show what the organization can document, where its economic record remains unclear, and what it can substantiate from its own systems.

Where Demand Originates
What Acquisition Actually Costs
Whether Referral Relationships Persist
How Care Transitions Convert
What Reenters the System
How Capacity Behaves
ECONOMICS FIREWALL

The Exhibit is corroborative and independent of the structural determination. It does not audit or value the enterprise, forecast performance, or alter the ICA™ score, maturity classification, or structural determination.

INSTITUTIONAL CONTINUITY REVIEW

Assessment Process

The Institutional Continuity Assessment™ is a remote executive structural review that examines whether an organization can demonstrate continuity beyond the treatment episode through its own evidence, leadership systems, and institutional records.
On-site evaluation is not required.
Determination

The ICA™ is a standalone institutional assessment.

Its determination creates no obligation to purchase, implement, or engage any subsequent Recovery Matters® service.
The assessment establishes the organization’s present structural condition. What the organization does next remains a separate institutional decision.
BOARD, INVESTOR & INSTITUTIONAL REVIEW

Initiate Institutional Continuity Assessment

Financial performance shows what the organization earned.
The ICA™ reveals the continuity exposure that may be eroding future earnings, referral value, and enterprise value—while increasing institutional risk.

For governing boards, investors, private equity sponsors, and executive leadership, the unanswered question is what the organization can demonstrate after discharge. Submission initiates a bounded assessment of five structural indicators and continuity economics, resulting in an evidence-supported Continuity Capacity Score™, structural determination, and Structural Readiness Report.

Controlled Evidence Review Leadership Architecture Interviews Five-Indicator Scoring Continuity Economics Exhibit Structural Readiness Report

The ICA™ is not a valuation, financial audit, or clinical quality rating. It establishes what the organization can presently evidence about continuity beyond discharge.

Initiate Institutional Assessment
Engagements may be initiated by executive leadership, governing boards, investors, transaction sponsors, or authorized institutional stakeholders.